君圣泰医药－Ｂ 02511Prospectus Information

Prospectus Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
IPO Timeline
Broker Results (T-2)
2023-12-20
Some brokers release in afternoon
Grey Market (T-1)
2023-12-21
Afternoon
HKEX Allotment (T-1)
2023-12-21
Evening
Registrar Allotment (T-1)
2023-12-21
Evening
Listing Day (T)
2023-12-22
First day of trading
Company Overview
Stock Name君圣泰医药－Ｂ
Stock Code02511
Company Full Name君圣泰医药－Ｂ
Industry醫療保健
Principal Activities公司為一間生物制藥公司，專注于就代謝及消化系統疾病的治療發現、開發及商業化多功能及多靶點療法。
Listing Date2023-12-22
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省深圳市龍崗區吉華街道甘李二路中海信創新產業城18B-102
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.hightidetx.com/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data
Offering Information
Offering Mechanism To be extracted
Offer PriceHK$ 11.50 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share39.2%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 83,472,750
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 0
2 lots 1,000 HK$ 0
3 lots 1,500 HK$ 0
4 lots 2,000 HK$ 0
5 lots 2,500 HK$ 0
6 lots 3,000 HK$ 0
7 lots 3,500 HK$ 0
8 lots 4,000 HK$ 0
9 lots 4,500 HK$ 0
10 lots 5,000 HK$ 0
12 lots 6,000 HK$ 0
14 lots 7,000 HK$ 0
16 lots 8,000 HK$ 0
18 lots 9,000 HK$ 0
20 lots 10,000 HK$ 0
30 lots 15,000 HK$ 0
40 lots 20,000 HK$ 0
50 lots 25,000 HK$ 0
60 lots 30,000 HK$ 0
70 lots 35,000 HK$ 0
80 lots 40,000 HK$ 0
90 lots 45,000 HK$ 0
100 lots 50,000 HK$ 0
120 lots 60,000 HK$ 0
140 lots 70,000 HK$ 0
160 lots 80,000 HK$ 0
180 lots 90,000 HK$ 0
200 lots 100,000 HK$ 0
300 lots 150,000 HK$ 0
400 lots 200,000 HK$ 0
500 lots 250,000 HK$ 0
600 lots 300,000 HK$ 0
700 lots 350,000 HK$ 0
800 lots 400,000 HK$ 0
900 lots 450,000 HK$ 0
1,000 lots 500,000 HK$ 0
1,200 lots 600,000 HK$ 0
1,400 lots 700,000 HK$ 0
1,600 lots 800,000 HK$ 0
1,800 lots 900,000 HK$ 0
2,000 lots 1,000,000 HK$ 0
2,200 lots 1,100,000 HK$ 0
2,419 lots 1,209,500 HK$ 0
Valuation & Financials
Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)To be extracted
P/E RatioTo be extracted
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 12.38
First Day OpenHK$ 11.92
First Day Change7.65%
First Day Volume5106500.0
First Day Turnover61579300.0
Use of Proceeds
Use of Proceeds1、約155.2百萬港元（相當于所得款項凈額的80%）將用于為核心產品HTD1801的持續臨床研發活動提供資金； 2、約9.7百萬港元（相當于所得款項凈額的5%）將用于為肥胖癥的HTD1804的持續研發提供資金； 3、約19.5百萬港元（相當于所得款項凈額的10%）將用于透過持續升級及加強FUSIONTXTM開發方式進行其他候選藥物的早期藥物發現及開發； 4、約9.7百萬港元（相當于所得款項凈額的5%）將用作營運資金及其他一般企業用途。
Underwriting Syndicate
Joint Sponsors (2)
UBS Securities Hong Kong Limited CE BIN466 华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (7)
UBS Securities Hong Kong Limited CE BIN466 华泰金融控股（香港）有限公司 CE AOK809 中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 越秀证券有限公司 CE ABQ722 建银国际金融有限公司 CE AJO225
Joint Bookrunners (13)
UBS Securities Hong Kong Limited CE BIN466 华泰金融控股（香港）有限公司 CE AOK809 中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 越秀证券有限公司 CE ABQ722 建银国际金融有限公司 CE AJO225 复星国际证券有限公司 CE AAF432 金联证券有限公司 CE BHH779 一盈证券有限公司 CE BJB315 申万宏源证券（香港）有限公司 CE AAC927 盈立证券有限公司 CE BJA907 盈宝证券国际（香港）有限公司 CE BRG131
Joint Lead Managers (13)
UBS Securities Hong Kong Limited CE BIN466 华泰金融控股（香港）有限公司 CE AOK809 中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 越秀证券有限公司 CE ABQ722 建银国际金融有限公司 CE AJO225 复星国际证券有限公司 CE AAF432 金联证券有限公司 CE BHH779 一盈证券有限公司 CE BJB315 申万宏源证券（香港）有限公司 CE AAC927 盈立证券有限公司 CE BJA907 盈宝证券国际（香港）有限公司 CE BRG131
Cornerstone Investors
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 沧州创融股权投资基金有限公司 109,106,250 HKD — 39.21% — 6 months 2024-06-22
Directors & Management
Chairman劉利平
Company Secretary高麗萍;朱璧敏
No director data available.
Major Shareholders
Major Shareholders & Holdings深圳市海普瑞藥業集團股份有限公司(23.61%);GREAT Mantra Group Limited(16.21%);百億投資有限公司(5.33%)
AI AI Analysis
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO of 君圣泰医药－Ｂ (02511) achieved a 32.22x oversubscription, indicating moderate retail demand but falling short of market frenzy levels. With a hit rate of 44.15%, over half of applicants walked away empty-handed, and the final offer price data is missing, limiting pricing commentary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Both A-tail and B-head applicants were allocated just 1 lot each, despite applying for 800 and 900 lots respectively—a mere 0.125% allocation, erasing the typical efficiency edge of B-head. This anomaly makes the B-head application cost-inefficient due to higher margin costs without any gain in shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

No demographic breakdown (Mainland/HK ratios, regional data) is available for this listing, possibly due to reporting gaps for pharmaceutical B-shares, limiting analysis of investor composition. Without this data, common trends like Guangdong dominance or mainland participation cannot be confirmed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

AI-generated content. For informational purposes only. Not financial advice. Verify against official sources.
Subscription Tiers
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics